ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Exclusion Criteria

• •History of another primary invasive malignancy that has not been in remission for at least 3 years
• •Current diagnosis of primary cutaneous CD30-positive T-cell lymphoproliferative disorders and lymphomas or mycosis fungoides
• •History of progressive multifocal leukoencephalopathy (PML)
• •Cerebral/meningeal disease related to the underlying malignancy